Journal of Postgraduate Medicine
 Open access journal indexed with Index Medicus & ISI's SCI  
Users online: 1049  
Home | Subscribe | Feedback | Login 
About Latest Articles Back-Issues Articlesmenu-bullet Search Instructions Online Submission Subscribe Etcetera Contact
 ::   Next article
 ::   Previous article
 ::   Table of Contents

 ::   Similar in PUBMED
 ::Related articles
 ::   Citation Manager
 ::   Access Statistics
 ::   Reader Comments
 ::   Email Alert *
 ::   Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded25    
    Comments [Add]    
    Cited by others 9    

Recommend this journal


Year : 2014  |  Volume : 60  |  Issue : 3  |  Page : 300-302

Bedaquiline: A novel antitubercular drug for multidrug-resistant tuberculosis

Department of Pharmacology, Mandya Institute of Medical Sciences, Mandya, Karnataka, India

Correspondence Address:
Dr. H Nagabushan
Department of Pharmacology, Mandya Institute of Medical Sciences, Mandya, Karnataka
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0022-3859.138772

Rights and Permissions

Multidrug-resistant and extensively drug-resistant tuberculosis (TB) are emerging global health threats. Bedaquiline is a new antituberculous drug belonging to the diarylquinoline class that efficiently inhibits the adenosine triphosphate synthase enzyme of Mycobacterium tuberculosis. It is a bactericidal and long-acting drug. It inhibits both dormant as well as replicating bacterial sub-populations and thus shortens the duration of TB treatment. This drug has been approved by the Food and Drug Administration in December 2012 for the management of multidrug resistant-TB. The drug marks the introduction of a new addition to the TB armamentarium after four decades.


Print this article     Email this article

Online since 12th February '04
2004 - Journal of Postgraduate Medicine
Official Publication of the Staff Society of the Seth GS Medical College and KEM Hospital, Mumbai, India
Published by Wolters Kluwer - Medknow